Regulatory News In Brief
This article was originally published in The Gray Sheet
FDA town hall meeting
You may also be interested in...
CDRH town halls – 2011 edition
White House scrutinizes human research
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.